Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 61

Results For "Biopharma"

711 News Found

Everest Medicines' trodelvy approved in Singapore for second-line metastatic triple-negative breast cancer
Drug Approval | February 08, 2022

Everest Medicines' trodelvy approved in Singapore for second-line metastatic triple-negative breast cancer

Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia


Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
Biotech | February 08, 2022

Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis

Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane


India grants Emergency Use Authorisation to Sputnik Light
News | February 07, 2022

India grants Emergency Use Authorisation to Sputnik Light

This is the ninth Covid-19 vaccine approved in India


Budget 22-23: Healthcare sector applauds focus on mental health
News | February 01, 2022

Budget 22-23: Healthcare sector applauds focus on mental health

A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook


Quantori names Arun Nayar as Global Head of R&D Informatics
People | January 26, 2022

Quantori names Arun Nayar as Global Head of R&D Informatics

New role strengthens Quantori’s global leadership position in data science & digital IT


Agilent announces the Innovative Seahorse XF Pro Analyzer
Medical Device | January 25, 2022

Agilent announces the Innovative Seahorse XF Pro Analyzer

Optimized for pharma/biopharma to deliver a deeper understanding of cellular function


Eplontersen granted Orphan Drug Designation in the US
Biotech | January 24, 2022

Eplontersen granted Orphan Drug Designation in the US

The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US


Lonza, Forbion, and BioGeneration to focus on manufacturing of small molecules
News | January 19, 2022

Lonza, Forbion, and BioGeneration to focus on manufacturing of small molecules

The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space


Dr Charles Woler is the new Chairman of Sygnature Discovery
People | January 17, 2022

Dr Charles Woler is the new Chairman of Sygnature Discovery

Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021


AstraZeneca studies show its booster effective against all variants
News | January 13, 2022

AstraZeneca studies show its booster effective against all variants

New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria